Market Indices
Sector Heatmap
ATR — AptarGroup, Inc.
NYSEAptarGroup, Inc.
- O
- 121.34
- H
- 121.97
- L
- 119.74
- V
- 382.42K
ATR — Latest News & Headlines
20 StoriesAptarGroup, Inc. (ATR) Stock Forecasts - Yahoo Finance
AptarGroup, Inc. (ATR) Stock Forecasts Yahoo Finance
Russian decree affects small AptarGroup (NYSE: ATR) unit - Stock Titan
Russian decree affects small AptarGroup (NYSE: ATR) unit Stock Titan
Confluence Investment Management LLC Sells 16,696 Shares of AptarGroup, Inc. $ATR - MarketBeat
Confluence Investment Management LLC Sells 16,696 Shares of AptarGroup, Inc. $ATR MarketBeat
Will MGH Research Tie Up Change Aptar Stock Narrative - Simply Wall Street
Will MGH Research Tie Up Change Aptar Stock Narrative Simply Wall Street
AptarGroup's Bottom Line Pressures Are Preventing An Upgrade (NYSE:ATR) - Seeking Alpha
AptarGroup's Bottom Line Pressures Are Preventing An Upgrade (NYSE:ATR) Seeking Alpha
Responsive Playbooks and the ATR Inflection - Stock Traders Daily
Responsive Playbooks and the ATR Inflection Stock Traders Daily
Teva Pharmaceutical (NYSE:TEVA) Nears Breakout With Perfect Technical Rating and Bull Flag Setup - ChartMill
Teva Pharmaceutical (NYSE:TEVA) Nears Breakout With Perfect Technical Rating and Bull Flag Setup ChartMill
These Dow Jones Stocks Buck Index's Dud Performance - Investor's Business Daily
These Dow Jones Stocks Buck Index's Dud Performance Investor's Business Daily
REG - Schroder AsianTR Inv - Results of the Scheme and Issue of New Shares - TradingView
REG - Schroder AsianTR Inv - Results of the Scheme and Issue of New Shares TradingView
AptarGroup (ATR) Could Be 20% Undervalued On MGH Research Partnership - Yahoo Finance
AptarGroup (ATR) Could Be 20% Undervalued On MGH Research Partnership Yahoo Finance
AptarGroup, Inc. (NYSE:ATR) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
AptarGroup, Inc. (NYSE:ATR) Receives Consensus Recommendation of "Moderate Buy" from Analysts MarketBeat
Some targeted cancer drugs cause painful rashes in about 50%–80% of patients. Azitra can now enroll a second group. - Stock Titan
Some targeted cancer drugs cause painful rashes in about 50%–80% of patients. Azitra can now enroll a second group. Stock Titan
Can AptarGroup (ATR) Justify Its Price After The MGH Research Agreement? - Simply Wall Street
Can AptarGroup (ATR) Justify Its Price After The MGH Research Agreement? Simply Wall Street
Valero Energy (NYSE:VLO) Breakout Setup Backed by 10/10 Technical Strength - ChartMill
Valero Energy (NYSE:VLO) Breakout Setup Backed by 10/10 Technical Strength ChartMill
RCS - Schroder AsianTR Inv - Results analysis from Kepler Trust Intelligence - TradingView
RCS - Schroder AsianTR Inv - Results analysis from Kepler Trust Intelligence TradingView
Zacks Research Estimates AptarGroup's Q3 Earnings (NYSE:ATR) - MarketBeat
Zacks Research Estimates AptarGroup's Q3 Earnings (NYSE:ATR) MarketBeat
Quanta Services (NYSE:PWR) Sets Up for Breakout With 8/8 Technical and Setup Ratings - ChartMill
Quanta Services (NYSE:PWR) Sets Up for Breakout With 8/8 Technical and Setup Ratings ChartMill
Zacks Research Forecasts AptarGroup's Q3 Earnings (NYSE:ATR) - MarketBeat
Zacks Research Forecasts AptarGroup's Q3 Earnings (NYSE:ATR) MarketBeat
BP (NYSE:BP) Builds a High-Quality Breakout Setup as Technical Strength Meets Tight Consolidation - ChartMill
BP (NYSE:BP) Builds a High-Quality Breakout Setup as Technical Strength Meets Tight Consolidation ChartMill
Agnico Eagle Mines (NYSE:AEM) Stock Nears Breakout With Strong Technical Setup - ChartMill
Agnico Eagle Mines (NYSE:AEM) Stock Nears Breakout With Strong Technical Setup ChartMill